Business

Medical technology, medical device and hospital trade groups are pushing the Trump administration for tariff exemptions on medical equipment
Consultants at PwC and BCG say manufacturers are looking to switch production to lower-tariff countries, more so than bringing production back to the U.S.
J&J forecasts $400 million tariff impact on its MedTech division
U.S. makers of personal protection equipment are applauding the new tariffs on Chinese goods, hoping they will help level the playing field here at home

President Donald Trump’s tariffs are creating a divide in the medical community.
Medical devices and protective gear made in China, Mexico and Canada were exempt from duties during the first Trump administration, but so far have not gotten a reprieve from his newest round of levies. While device makers who would take a big hit from the tariffs are pushing for a new carve out, the makers of personal protective equipment — who stand to benefit from the barriers — are not.  

The duties could also increase costs for hospitals — and therefore patients — and reduce access to critical equipment and care.
“MedTech supply chain leaders are already reporting supply chain concerns, and we cannot afford to drive up the cost of health care for patients, or on the health care system,” said Scott Whitaker, CEO of AdvaMed, the trade group which represents medical technology and device makers. “The reality is, any increased costs will be largely borne by taxpayer-funded health programs like Medicare, Medicaid and the VA.”
Hospital trade groups have also been sounding the alarm, saying that tariffs could reduce the quality of care.
“The AHA has and will continue to share with the Administration, disruptions in the availability of these critical devices — many of which are sourced internationally — have the potential to disrupt patient care,” said Rick Pollack, the CEO of the American Hospital Association. “AHA continues to push for a tariff exemption for medical devices to ensure that hospitals and health systems can continue to serve their patients and communities.”

Tariffs add pricing complexity

WUHAN, CHINA – APRIL 08: Models of United Imaging medical devices are on display during the 7th World Health Expo on April 8, 2025 in Wuhan, Hubei Province of China.
Zhang Chang | China News Service | Getty Images

Trump in February imposed 25% tariffs on imports from Canada and Mexico, but later delayed duties on many items that fall under the U.S.-Mexico-Canada Agreement.

There has been no reprieve for goods from China. Trump’s new levies on imports from the country during his second term have brought the tariff rate up to 145%.
Dozens of other countries face 10% tariffs after Trump delayed proposed steeper rates.

Medical equipment seller squeezed

Many businesses can simply raise their prices to help offset increased costs from tariffs. That doesn’t apply to a range of hospitals and other organizations buying medical equipment.
Many of those groups will have trouble passing on higher costs under current insurance coverage contracts, which they say have locked in prices for the year.
“With the level of tariffs that we’re looking at in China, businesses are going to be completely upside down on these products … they can’t pass those costs on to the consumer.,” explained Casey Hite, CEO of Aeroflow Health, a firm which provides insurance-covered medical devices ranging from breast pumps for nursing mothers to CPAP machines for sleep apnea patients.  
Hite spent last week lobbying members of Congress on Capitol Hill for an overall MedTech tariff exemption — or at the very least more time to adjust.
“I think what we would like to see, more than anything, is a runway or some predictability,” Hite said, adding “let’s do this over the next 12 months, next two years, so that U.S. organizations can prepare.”

PPE makers see tariff boost  

On the opposite end of the tariff divide, U.S. companies that produce personal protective equipment have applauded the Trump administration’s latest levies on China.
“I don’t know if it’s going to help the economy overall, but I do know that in our case, successive administrations — both Republican and Democratic — have recognized that these products are not competing on a level playing field,” said Eric Axel, CEO of the American Medical Manufacturers Association, the trade group which represents PPE Makers.
Analysts at Boston Consulting Group estimate roughly half of PPE used in the U.S. is produced in China, with roughly 10%-15% in Canada and Mexico.
The latest tariffs will add to duties imposed on PPE by the Biden administration last fall, which included 100% levies on syringes and needles imported from China. Those items will now face a total 245% tariff.
Altor Safety, which manufactures masks, N95 respirators and gloves in the U.S., has welcomed the tariffs on China. The PPE maker contracts with the U.S. government and companies like FedEx, but has not been able to gain much market share with health systems because Chinese manufacturers subsidized by Beijing undercut U.S. manufacturers on price.
Altor president Thomas Allen said the new tariffs could help the company win new contracts, adding that as Altor increases capacity, “we can actually lower our prices.”

The challenges of U.S. manufacturing

Trump has said he has imposed tariffs in large part to encourage manufacturing in the U.S. In the case of PPE, that may not happen.
But near term, consulting firms say multinational producers are looking to shift manufacturing away from China to other countries with lower tariffs rather than bring it back to the U.S.
“Managing that and the complexity there becomes super hard,” explained Vikram Aggarwal, a BCG managing director and partner.
For American-based medical device and protective gear manufacturers, one strategy now is to shift international production to Mexico and Canada, where they can potentially secure exemptions for products made under USMCA.
Many of the major medical technology and device makers produce many of their goods in the U.S., but do have multiple points for manufacturing internationally. Analysts at Canaccord Genuity note Zimmer Biomet and Stryker, two of the largest makers of knee replacements, have dozens of facilities across North America, Europe and Asia that help them navigate tariffs, but will still face a financial impact.

J&J sees $400 million tariff impact

Johnson & Johnson calculates that its MedTech division, which produces orthopedic and cardiac implants, could face a $400 million dollar tariff headwind this year, due in large part to the magnitude of duties on Chinese imports, as well as levies on non-USMCA compliant imports from Canada and Mexico.
It was one of the first MedTech firms to report first-quarter results and give a glimpse into the effects of tarrifs. CFO Joseph Wolk told analysts on the company’s earnings call that existing contracts with hospitals make it hard to raise prices in the near term.
Longer term, J&J CEO Joaquin Duato said the disruptive nature of tariffs does not create the right incentive to boost manufacturing in the U.S.
“If what you want is to build manufacturing capacity in the U.S., both in MedTech and in pharmaceuticals, the most effective answer is not tariffs but tax policy,” Duato said, noting the company is already investing $55 billion over four years to produce its advanced medications in America.
“Tax policy is a very effective tool to be able to build manufacturing capacity here in the U.S., both for MedTech and pharmaceuticals,” he added. More

Heineken first-quarter revenue beat estimates and it maintained its full-year outlook, but beer sales waned.
The company’s CEO previously described President Donald Trump’s tariffs as “relatively manageable,” but now the company says it must remain “agile.”
The 25% tariff on imported canned beer and empty aluminum cans that went into effect on April 4 remains in place.

Imported beer, including Heineken, for sale at a store in New York City on April 10, 2025. 
Timothy A. Clary | Afp | Getty Images

Heineken shrugged off the threat of tariffs earlier this year, but now the company is raising more concerns about potential disruptions to its business.
In the Dutch brewer’s earnings report released Wednesday, Heineken indicated new U.S. tariffs, particularly those targeting canned beer, could force it to adjust spending and investments.

“There are broader uncertainties, including recent tariff adjustments and potential increases, as we go forward,” the company said in its earnings release. “To navigate this fluctuating environment, we remain agile in our allocation of capital and resources.”
While Trump’s steep tariff rates on dozens of countries remain in flux under a 90-day pause, he has maintained the 25% duty on imported canned beer and empty aluminum cans that went into effect earlier this month.
Heineken reported first-quarter revenue growth that beat analysts’ expectations on Wednesday morning and affirmed its full-year guidance despite the tariff risks. But its beer sales fell 2.1% in the first quarter.
CEO Dolf van den Brink said the company expected weaker beer sales, given ongoing risks from inflation, weak consumer sentiment, and currency fluctuations, in addition to the uncertainty surrounding global tariffs.

Van den Brink’s comments mark a departure from earlier statements in February, when he described proposed U.S. tariffs, including those on aluminum used in beer cans, as “relatively manageable.”

“The beer industry is capital intensive and it’s very local. So, as such, it’s an industry that’s a bit less susceptible to disruption in international trade flows,” he told “Squawk Box Europe” in February.
At that time, AB InBev, the world’s largest brewer and owner of brands including Budweiser and Stella Artois, similarly downplayed the threat of tariffs.
“We don’t think that we’re going to have big topics to discuss during this year in terms of tariffs,” CEO Michel Doukeris said.
But now, a growing global trade conflict has led Heineken and others to reassess.
Constellation Brands reported a quarterly earnings beat last week, but lowered its long-term guidance for 2027 and 2028, citing in part “the anticipated impact of tariffs.”
“The guidance that we have provided reflects the fact that there are a lot of unknowns today, including things like tariffs,” said CEO Bill Newlands. More

Plastic is ubiquitous. Around 1m plastic water bottles are sold every minute and 5trn plastic bags are used around the world every year, according to the un’s Environment Programme. Half of all production, which is growing faster than that of any other material, is designed for single-use applications. The world’s annual output of over 400m tonnes is set to reach 1,100m by 2050. Mountains of waste mean pressure from both the public and regulators to improve recycling. More

“Nobody is getting off the hook for unfair trade balances,” insists Donald Trump. The exemptions and exclusions to the tariffs he has imposed on imports to America would suggest otherwise. His “reciprocal” tariffs announced on April 2nd included a 37-page annexe with exemptions for $644bn-worth of American imports, about a fifth of the total. On April 11th another 20 products were exempted, including smartphones and computers. More

“The future is bright” is a phrase rarely uttered by European business leaders these days. But José Manuel Entrecanales, the chief executive of Acciona, is brimming with optimism for both Spanish business and his family’s company, which he has transformed from a construction firm to one focused on renewable-energy infrastructure. He reflects a mood in Madrid that is happy and enthusiastic—in contrast to the anxiety in Berlin or Paris. More

Congratulate LinkedIn on its work anniversary! Next month the business world’s favourite social network will turn 22. The 1.1bn users of LinkedIn—which is a year older than even Facebook—can celebrate two decades of humblebrags, motivational quotes and automated congratulations from long-forgotten acquaintances. Microsoft, its owner, can meanwhile toast a canny acquisition. Since the tech giant bought LinkedIn eight years ago, for $26bn, the platform’s annual revenue has grown from $3bn to $17bn. More

AS DONALD TRUMP’S tariff tantrum destroyed trillions of dollars in shareholder value, shrieks of horror from American chief executives grew high-pitched. If you think America Inc had it bad, then spare a thought for Hong Kong. The self-governing Chinese territory is the world’s gateway to Asia, and China in particular. It is also Asia’s, and China’s, gateway to the world. And for the trade-warmonger-in-chief, China and Asia are enemies number one and two. More

When Monica Lewinsky, once an intern at the White House, was cajoled into a lunch date by Linda Tripp, a colleague wearing a wire, she was met by fbi agents and taken to a room in Washington’s Ritz-Carlton Hotel to be interrogated. What seemed like an innocent lunch date was one of the first steps towards a presidential impeachment. Yet one of the more remarkable aspects of the story is that even lowly workers took lunch in a restaurant back in those days. More